{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:01:37Z","timestamp":1783512097544,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1537"],"award-info":[{"award-number":["1537"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The emergence of carbapenem-resistant and extensively drug-resistant (XDR)\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      as well as inadequate effective antibiotics calls for an urgent effort to find new antibacterial agents. The therapeutic efficacy of two human scFvs, EB211 and EB279, showing growth inhibitory activity against\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      in\n                      <jats:italic>vitro<\/jats:italic>\n                      , was investigated in immunocompromised mice with\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      pneumonia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The data revealed that infected mice treated with EB211, EB279, and a combination of the two scFvs showed better survival, reduced bacterial load in the lungs, and no marked pathological abnormalities in the kidneys, liver, and lungs when compared to the control groups receiving normal saline or an irrelevant scFv.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results from this study suggest that the scFvs with direct growth inhibitory activity could offer promising results in the treatment of pneumonia caused by XDR\n                      <jats:italic>A. baumannii.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12866-023-03080-9","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T04:02:24Z","timestamp":1707537744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-Acinetobacter baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model"],"prefix":"10.1186","volume":"24","author":[{"given":"Eilnaz","family":"Basardeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Piri-Gavgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Mirzabeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Ghanei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Mahboudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rahimi-Jamnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"issue":"8","key":"3080_CR1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cmi.2017.10.033","volume":"24","author":"CA Liang","year":"2018","unstructured":"Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. Antibiotic strategies and clinical outcomes in critically ill patients with Pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24(8):908\u2013e1.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"3080_CR2","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","volume":"10","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK. Contemporary perspective on the treatment of Acinetobacter baumannii Infections: insights from the Society of Infectious Diseases pharmacists. Infect Dis Ther. 2021;10(4):2177\u2013202.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"3080_CR3","doi-asserted-by":"publisher","first-page":"e0197521","DOI":"10.1128\/aac.01975-21","volume":"66","author":"HJ Appaneal","year":"2022","unstructured":"Appaneal HJ, Lopes VV, LaPlante KL, Caffrey AR, Treatment. Clinical outcomes, and predictors of mortality among a National Cohort of admitted patients with Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2022;66(3):e0197521.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3080_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/antibiotics11081015","volume":"11","author":"F Medioli","year":"2022","unstructured":"Medioli F, Bacca E, Faltoni M, Burastero GJ, Volpi S, Menozzi M, et al. Is it possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from endemic hospitals? Antibiotics. 2022;11(8):1015.","journal-title":"Antibiotics"},{"key":"3080_CR5","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2147\/IDR.S349895","volume":"15","author":"H Hu","year":"2022","unstructured":"Hu H, Lou Y, Feng H, Tao J, Shi W, Ni S, et al. Molecular characterization of Carbapenem-Resistant Acinetobacter baumannii isolates among Intensive Care Unit patients and Environment. Infect Drug Resist. 2022;15:1821\u201329.","journal-title":"Infect Drug Resist"},{"issue":"8","key":"3080_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3855\/jidc.4248","volume":"8","author":"A Kumar","year":"2014","unstructured":"Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream Infections in a neonatal intensive care unit, Delhi, India. J Infect Dev Ctries. 2014;8(8):1049\u201354.","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"3080_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"C-J Jung","year":"2021","unstructured":"Jung C-J, Liao Y-D, Hsu C-C, Huang T-Y, Chuang Y-C, Chen J-W, et al. Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of Pneumonia. Sci Rep. 2021;11(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"3","key":"3080_CR8","first-page":"373","volume":"10","author":"I Kyriakidis","year":"2021","unstructured":"Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii Antibiotic Resistance Mechanisms Pathogens. 2021;10(3):373.","journal-title":"Acinetobacter baumannii Antibiotic Resistance Mechanisms Pathogens"},{"issue":"3","key":"3080_CR9","doi-asserted-by":"publisher","first-page":"e01254","DOI":"10.1128\/mBio.01254-20","volume":"11","author":"BJC Walsh","year":"2020","unstructured":"Walsh BJC, Wang J, Edmonds KA, Palmer LD, Zhang Y, Trinidad JC, et al. The response of Acinetobacter baumannii to Hydrogen Sulfide reveals two Independent persulfide-sensing systems and a connection to Biofilm Regulation. mBio. 2020;11(3):e01254\u201320.","journal-title":"mBio"},{"issue":"8","key":"3080_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/antibiotics9080514","volume":"9","author":"X Zhen","year":"2020","unstructured":"Zhen X, Stalsby Lundborg C, Sun X, Gu S, Dong H. Clinical and economic Burden of Carbapenem-resistant Infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a Multicenter Study in China. Antibiotics. 2020;9(8):514.","journal-title":"Antibiotics"},{"key":"3080_CR11","doi-asserted-by":"publisher","first-page":"814193","DOI":"10.3389\/fimmu.2022.814193","volume":"13","author":"M Magda","year":"2022","unstructured":"Magda M, Bettoni S, Laabei M, Fairley D, Russo TA, Riesbeck K, et al. Clinical isolates of Acinetobacter spp. are highly serum resistant despite efficient recognition by the complement system. Front Immunol. 2022;13:814193.","journal-title":"Front Immunol"},{"issue":"7","key":"3080_CR12","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.ajic.2013.01.006","volume":"41","author":"YL Zheng","year":"2013","unstructured":"Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii Pneumonia. Am J Infect Control. 2013;41(7):e59\u201363.","journal-title":"Am J Infect Control"},{"issue":"8","key":"3080_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","volume":"25","author":"ET Piperaki","year":"2019","unstructured":"Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"3080_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/19420862.2016.1196521","volume":"8","author":"G Desoubeaux","year":"2016","unstructured":"Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, et al. Therapeutic monoclonal antibodies for Respiratory Diseases: current challenges and perspectives, March 31 - April 1, 2016, tours, France. MAbs. 2016;8(6):999\u20131009.","journal-title":"MAbs"},{"key":"3080_CR15","doi-asserted-by":"publisher","first-page":"673239","DOI":"10.3389\/fphar.2021.673239","volume":"12","author":"B Yang","year":"2021","unstructured":"Yang B, Fang D, Lv Q, Wang Z, Liu Y. Targeted therapeutic strategies in the battle against pathogenic Bacteria. Front Pharmacol. 2021;12:673239.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3080_CR16","doi-asserted-by":"publisher","first-page":"ltaa007","DOI":"10.1093\/immadv\/ltaa007","volume":"1","author":"D Ramamurthy","year":"2021","unstructured":"Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K, et al. Recent advances in immunotherapies against infectious Diseases. Immunother Adv. 2021;1(1):ltaa007.","journal-title":"Immunother Adv"},{"issue":"9","key":"3080_CR17","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/biomedicines10092126","volume":"10","author":"F Vacca","year":"2022","unstructured":"Vacca F, Sala C, Rappuoli R. Monoclonal antibodies for bacterial pathogens: mechanisms of Action and Engineering approaches for enhanced effector functions. Biomedicines. 2022;10(9):2126.","journal-title":"Biomedicines"},{"issue":"3","key":"3080_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/QCO.0000000000000539","volume":"32","author":"MP Motley","year":"2019","unstructured":"Motley MP, Banerjee K, Fries BC. Monoclonal antibody-based therapies for bacterial Infections. Curr Opin Infect Dis. 2019;32(3):210\u201316.","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"3080_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mSphere.00397-17","volume":"2","author":"MP Motley","year":"2017","unstructured":"Motley MP, Fries BC. A New take on an old remedy: Generating antibodies against Multidrug-Resistant Gram-negative Bacteria in a Postantibiotic World. mSphere. 2017;2(5):10\u201328.","journal-title":"mSphere"},{"issue":"6","key":"3080_CR20","doi-asserted-by":"publisher","first-page":"e02588","DOI":"10.1128\/AAC.02588-18","volume":"63","author":"M Peck","year":"2019","unstructured":"Peck M, Rothenberg ME, Deng R, Lewin-Koh N, She G, Kamath AV, et al. A phase 1, Randomized, single-ascending-dose study to investigate the Safety, Tolerability, and pharmacokinetics of DSTA4637S, an Anti-Staphylococcus Aureus Thiomab antibody-antibiotic Conjugate, in healthy volunteers. Antimicrob Agents Chemother. 2019;63(6):e02588\u201302518.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3080_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/antib7010005","volume":"7","author":"SX Wang-Lin","year":"2018","unstructured":"Wang-Lin SX, Balthasar JP. Pharmacokinetic and pharmacodynamic considerations for the use of monoclonal antibodies in the treatment of bacterial Infections. Antibodies. 2018;7(1):5.","journal-title":"Antibodies"},{"issue":"3","key":"3080_CR22","first-page":"e00086","volume":"67","author":"M Slarve","year":"2023","unstructured":"Slarve M, Reyna Z, Burk E, Ruiz-Delgado J, Li R, Yan J, et al. Therapeutic, humanized monoclonal antibody exhibits broad binding and protective efficacy against Acinetobacter baumannii. Antimicrob Agents Chemother. 2023;67(3):e00086\u201300023.","journal-title":"Antimicrob Agents Chemother"},{"key":"3080_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/jiac499","volume":"227","author":"TB Nielsen","year":"2023","unstructured":"Nielsen TB, Yan J, Slarve M, Li R, Junge JA, Luna BM, et al. Development of a bispecific antibody targeting clinical isolates of Acinetobacter baumannii. J Infect Dis. 2023;227:1042\u201349.","journal-title":"J Infect Dis"},{"issue":"4","key":"3080_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/infdis\/jix315","volume":"216","author":"TB Nielsen","year":"2017","unstructured":"Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, et al. Monoclonal antibody protects against Acinetobacter baumannii Infection by enhancing bacterial clearance and evading sepsis. J Infect Dis. 2017;216(4):489\u2013501.","journal-title":"J Infect Dis"},{"issue":"10","key":"3080_CR25","doi-asserted-by":"publisher","first-page":"e00162","DOI":"10.1128\/IAI.00162-21","volume":"89","author":"TB Nielsen","year":"2021","unstructured":"Nielsen TB, Yan J, Slarve M, Lu P, Li R, Ruiz J, et al. Monoclonal antibody therapy against Acinetobacter baumannii. Infect Immun. 2021;89(10):e00162\u201300121.","journal-title":"Infect Immun"},{"issue":"1","key":"3080_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81356-8","volume":"11","author":"A Jahangiri","year":"2021","unstructured":"Jahangiri A, Owlia P, Rasooli I, Salimian J, Derakhshanifar E, Aghajani Z, et al. Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii Pneumonia Infection. Sci Rep. 2021;11(1):1\u201311.","journal-title":"Sci Rep"},{"key":"3080_CR27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1021\/acsinfecdis.3c00024","volume":"9","author":"GA Knauf","year":"2023","unstructured":"Knauf GA, Groover KE, O\u2019Donnell AC, Davies BW. Generation of Synthetic Acinetobacter baumannii-Specific nanobodies. ACS Infect Dis. 2023;9:1190\u201395.","journal-title":"ACS Infect Dis"},{"key":"3080_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","volume":"14","author":"R Ahamadi-Fesharaki","year":"2019","unstructured":"Ahamadi-Fesharaki R, Fateh A, Vaziri F, Solgi G, Siadat SD, Mahboudi F, et al. Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow. Mol Ther Oncolytics. 2019;14:38.","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"3080_CR29","doi-asserted-by":"publisher","first-page":"e0276786","DOI":"10.1371\/journal.pone.0276786","volume":"17","author":"T Di Mambro","year":"2022","unstructured":"Di Mambro T, Vanzolini T, Bianchi M, Crinelli R, Canonico B, Tasini F, et al. Development and in vitro characterization of a humanized scFv against fungal Infections. PLoS ONE. 2022;17(10):e0276786.","journal-title":"PLoS ONE"},{"issue":"7","key":"3080_CR30","doi-asserted-by":"publisher","first-page":"e1302","DOI":"10.1002\/cti2.1302","volume":"10","author":"B Soltanmohammadi","year":"2021","unstructured":"Soltanmohammadi B, Piri-Gavgani S, Basardeh E, Ghanei M, Azizi M, Khaksar Z, et al. Bactericidal fully human single-chain fragment variable antibodies protect mice against methicillin-resistant Staphylococcus aureus bacteraemia. Clin Transl Immunol. 2021;10(7):e1302.","journal-title":"Clin Transl Immunol"},{"issue":"4","key":"3080_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.biotechadv.2009.04.004","volume":"27","author":"NE Weisser","year":"2009","unstructured":"Weisser NE, Hall JC. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv. 2009;27(4):502\u201320.","journal-title":"Biotechnol Adv"},{"issue":"9","key":"3080_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nbt1142","volume":"23","author":"P Holliger","year":"2005","unstructured":"Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126\u201336.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"3080_CR33","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00253-015-7045-8","volume":"100","author":"M Wang","year":"2016","unstructured":"Wang M, Zhang Y, Zhu J. Anti-Staphylococcus Aureus single-chain variable region fragments provide protection against mastitis in mice. Appl Microbiol Biotechnol. 2016;100(5):2153\u201362.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"4","key":"3080_CR34","doi-asserted-by":"publisher","first-page":"e02168","DOI":"10.1128\/AAC.02168-19","volume":"64","author":"G Richard","year":"2020","unstructured":"Richard G, MacKenzie CR, Henry KA, Vinogradov E, Hall JC, Hussack G. Antibody binding to the O-Specific Antigen of Pseudomonas aeruginosa O6 inhibits cell growth. Antimicrob Agents Chemother. 2020;64(4):e02168\u201302119.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3080_CR35","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.4049\/jimmunol.0902732","volume":"184","author":"X Xie","year":"2010","unstructured":"Xie X, McLean MD, Hall JC. Antibody-dependent cell-mediated cytotoxicity-and complement-dependent cytotoxicity-independent bactericidal activity of an IgG against Pseudomonas aeruginosa O6ad. J Immunol. 2010;184(7):3725\u201333.","journal-title":"J Immunol"},{"issue":"6","key":"3080_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F","volume":"47","author":"Z Oren","year":"1998","unstructured":"Oren Z, Shai Y. Mode of action of linear amphipathic \u03b1-helical antimicrobial peptides. Pept Sci. 1998;47(6):451\u201363.","journal-title":"Pept Sci"},{"key":"3080_CR37","volume-title":"Investigating the bactericidal mechanism of Anti-LPS antibodies against Pseudomonas aeruginosa Serotype O6","author":"G Richard","year":"2017","unstructured":"Richard G. Investigating the bactericidal mechanism of Anti-LPS antibodies against Pseudomonas aeruginosa Serotype O6. Ontario, Canada: University of Guelph; 2017."},{"issue":"9","key":"3080_CR38","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.4049\/jimmunol.180.9.6222","volume":"180","author":"TJ LaRocca","year":"2008","unstructured":"LaRocca TJ, Katona LI, Thanassi DG, Benach JL. Bactericidal action of a complement-independent antibody against relapsing Fever Borrelia resides in its variable region. J Immunol. 2008;180(9):6222\u201328.","journal-title":"J Immunol"},{"issue":"9","key":"3080_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1078\/0171-9335-00411","volume":"83","author":"A Nasirudeen","year":"2004","unstructured":"Nasirudeen A, Tan KS. Caspase-3-like protease influences but is not essential for DNA fragmentation in Blastocystis undergoing apoptosis. Eur J Cell Biol. 2004;83(9):477\u201382.","journal-title":"Eur J Cell Biol"},{"key":"3080_CR40","first-page":"1141","volume":"25","author":"E Basardeh","year":"2022","unstructured":"Basardeh E, Piri-Gavgani S, Soltanmohammadi B, Ghanei M, Omrani MD, Soezi M, et al. Anti-Acinetobacter Baumannii single-chain variable fragments show direct bactericidal activity. Iran J Basic Med Sci. 2022;25:1141\u201349.","journal-title":"Iran J Basic Med Sci"},{"issue":"26","key":"3080_CR41","doi-asserted-by":"publisher","first-page":"10752","DOI":"10.1073\/pnas.0901858106","volume":"106","author":"TJ LaRocca","year":"2009","unstructured":"LaRocca TJ, Holthausen DJ, Hsieh C, Renken C, Mannella CA, Benach JL. The bactericidal effect of a complement-independent antibody is osmolytic and specific to Borrelia. PNAS. 2009;106(26):10752\u201357.","journal-title":"PNAS"},{"issue":"3","key":"3080_CR42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1128\/IAI.01184-12","volume":"81","author":"TA Russo","year":"2013","unstructured":"Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St. Michael F, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013;81(3):915\u201322.","journal-title":"Infect Immun"},{"issue":"3","key":"3080_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.118.253617","volume":"368","author":"SX Wang-Lin","year":"2019","unstructured":"Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Russo TA, Balthasar JP. Antibody dependent enhancement of Acinetobacter baumannii Infection in a mouse Pneumonia model. J Pharmacol Exp Ther. 2019;368(3):475\u201389.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"3080_CR44","doi-asserted-by":"publisher","first-page":"e00591","DOI":"10.1128\/IAI.00591-17","volume":"85","author":"SX Wang-Lin","year":"2017","unstructured":"Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Balthasar JP, Russo TA. The capsular polysaccharide of Acinetobacter baumannii is an obstacle for therapeutic passive immunization strategies. Infect Immun. 2017;85(12):e00591\u201317.","journal-title":"Infect Immun"},{"issue":"1","key":"3080_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2180-1-16","volume":"1","author":"VK Goel","year":"2001","unstructured":"Goel VK, Kapil A. Monoclonal antibodies against the iron regulated outer membrane proteins of Acinetobacter baumannii are bactericidal. BMC Microbiol. 2001;1(1):16.","journal-title":"BMC Microbiol"},{"issue":"5","key":"3080_CR46","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","volume":"75","author":"A Takada","year":"2001","unstructured":"Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol. 2001;75(5):2324\u201330.","journal-title":"J Virol"},{"issue":"8589","key":"3080_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S0140-6736(88)91657-1","volume":"331","author":"JRWE Robinson","year":"1988","unstructured":"Robinson JRWE, Montefiori D, Mitchell W. Antibody-dependent enhancement of human immunodeficiency virus type 1 Infection. Lancet. 1988;331(8589):790\u201394.","journal-title":"Lancet"},{"issue":"1","key":"3080_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/088282403763635465","volume":"16","author":"SM Tirado","year":"2003","unstructured":"Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus Infection and Disease. Viral Immunol. 2003;16(1):69\u201386.","journal-title":"Viral Immunol"},{"issue":"5979","key":"3080_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus Infection in humans. Science. 2010;328(5979):745\u201348.","journal-title":"Science"},{"issue":"10","key":"3080_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185\u201391.","journal-title":"Nat Microbiol"},{"issue":"2","key":"3080_CR51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/antib2020193","volume":"2","author":"P Monnier","year":"2013","unstructured":"Monnier P, Vigouroux R, Tassew N. In vivo applications of single chain fv (variable domain)(scFv) fragments. Antibodies. 2013;2(2):193\u2013208.","journal-title":"Antibodies"},{"key":"3080_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","volume":"8","author":"Z Li","year":"2016","unstructured":"Li Z, Krippendorff B-F, Sharma S, Walz AC, Lav\u00e9 T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs. 2016;8:113\u201319.","journal-title":"MAbs"},{"issue":"1","key":"3080_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-54180-4","volume":"9","author":"Y Huang","year":"2019","unstructured":"Huang Y, Furuno M, Arakawa T, Takizawa S, de Hoon M, Suzuki H, et al. A framework for identification of on-and off-target transcriptional responses to drug treatment. Sci Rep. 2019;9(1):1\u20139.","journal-title":"Sci Rep"},{"issue":"10","key":"3080_CR54","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.yexcr.2012.03.004","volume":"318","author":"FR Jamnani","year":"2012","unstructured":"Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Sharifzadeh Z. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing Tumor cells. Exp Cell Res. 2012;318(10):1112\u201324.","journal-title":"Exp Cell Res"},{"issue":"2","key":"3080_CR55","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","volume":"11","author":"C Bartal","year":"2022","unstructured":"Bartal C, Rolston KVI, Nesher L. Carbapenem-resistant Acinetobacter baumannii: colonization, Infection and current treatment options. Infect Dis Ther. 2022;11(2):683\u201394.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"3080_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics8010024","volume":"8","author":"RL Nation","year":"2019","unstructured":"Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin Acute kidney Injury: Dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1):24.","journal-title":"Antibiotics"},{"issue":"1","key":"3080_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/pharmaceutics14010031","volume":"14","author":"W Katip","year":"2021","unstructured":"Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the Loading Dose Colistin for the treatment of Carbapenem-Resistant Acinetobacter baumannii in critically Ill patients. Pharmaceutics. 2021;14(1):31.","journal-title":"Pharmaceutics"},{"issue":"8","key":"3080_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/membranes10080181","volume":"10","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck C. Polymyxins and bacterial membranes: a review of Antibacterial Activity and mechanisms of Resistance. Membranes. 2020;10(8):181.","journal-title":"Membranes"},{"issue":"30","key":"3080_CR59","first-page":"2020","volume":"2013","author":"W Underwood","year":"2020","unstructured":"Underwood W, Anthony R. AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March. 2020;2013(30):2020\u20131.","journal-title":"Retrieved on March"},{"issue":"1","key":"3080_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-74503-0","volume":"10","author":"X-L Ma","year":"2020","unstructured":"Ma X-L, Guo Y-Z, Wu Y-M, Gong W-T, Sun J, Huang Z. In vivo bactericidal effect of colistin\u2013linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii Pneumonia. Sci Rep. 2020;10(1):1\u20138.","journal-title":"Sci Rep"},{"key":"3080_CR61","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.micpath.2018.05.051","volume":"121","author":"N Irani","year":"2018","unstructured":"Irani N, Basardeh E, Samiee F, Fateh A, Shooraj F, Rahimi A, et al. The inhibitory effect of the combination of two new peptides on biofilm formation by Acinetobacter baumannii. Microb Pathog. 2018;121:310\u201317.","journal-title":"Microb Pathog"},{"issue":"262","key":"3080_CR62","doi-asserted-by":"publisher","first-page":"262ra155","DOI":"10.1126\/scitranslmed.3009655","volume":"6","author":"A DiGiandomenico","year":"2014","unstructured":"DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6(262):262ra155.","journal-title":"Sci Transl Med"},{"issue":"9","key":"3080_CR63","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1097\/CCM.0b013e3181a0f8e1","volume":"37","author":"SR Chiang","year":"2009","unstructured":"Chiang SR, Chuang YC, Tang HJ, Chen CC, Chen CH, Lee NY, et al. Intratracheal colistin sulfate for BALB\/c mice with early Pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med. 2009;37(9):2590\u201395.","journal-title":"Crit Care Med"},{"issue":"8","key":"3080_CR64","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1128\/AAC.00944-13","volume":"57","author":"G Harris","year":"2013","unstructured":"Harris G, Lee RK, Lam CK, Kanzaki G, Patel GB, et al. A mouse model of Acinetobacter baumannii-associated Pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013;57(8):3601\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3080_CR65","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1128\/IAI.00762-07","volume":"75","author":"H van Faassen","year":"2007","unstructured":"van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. Neutrophils play an important role in host resistance to Respiratory Infection with Acinetobacter baumannii in mice. Infect Immun. 2007;75(12):5597\u2013608.","journal-title":"Infect Immun"},{"issue":"1","key":"3080_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-53714-0","volume":"9","author":"NS Ku","year":"2019","unstructured":"Ku NS, Lee S-H, Lim Y-s, Choi H, Ahn JY, Jeong SJ, et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii Pneumonia. Sci Rep. 2019;9(1):1\u20137.","journal-title":"Sci Rep"},{"key":"3080_CR67","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fimmu.2020.00270","volume":"11","author":"MJ Kang","year":"2020","unstructured":"Kang MJ, Jang AR, Park JY, Ahn JH, Lee TS, Kim DY, et al. IL-10 protects mice from the lung Infection of Acinetobacter baumannii and contributes to bacterial clearance by regulating STAT3-Mediated MARCO expression in macrophages. Front Immunol. 2020;11:270.","journal-title":"Front Immunol"},{"issue":"11","key":"3080_CR68","doi-asserted-by":"publisher","first-page":"e0188251","DOI":"10.1371\/journal.pone.0188251","volume":"12","author":"K Dietert","year":"2017","unstructured":"Dietert K, Gutbier B, Wienhold SM, Reppe K, Jiang X, Yao L, et al. Spectrum of pathogen- and model-specific histopathologies in mouse models of acute Pneumonia. PLoS ONE. 2017;12(11):e0188251.","journal-title":"PLoS ONE"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-03080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-023-03080-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-03080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T10:05:59Z","timestamp":1709373959000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-023-03080-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3080"],"URL":"https:\/\/doi.org\/10.1186\/s12866-023-03080-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3130523\/v1","asserted-by":"object"}]},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"1 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were conducted in accordance with ARRIVE guidelines (\n                      \n                      ) and approved by the Animal Care and Use Committees of the Pasteur Institute of Iran (IR.PII.REC.1397.036). All methods were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}